100 related articles for article (PubMed ID: 28150013)
21. Duvelisib, a new PI3K inhibitor for lymphoid malignancies.
Lamanna N
Clin Adv Hematol Oncol; 2020 Oct; 18(10):606-608. PubMed ID: 33201865
[No Abstract] [Full Text] [Related]
22. Granulomatous rosacea-like facial eruption in an elderly man: leukaemia cutis.
Murad A; Fortune A; O' Keane C; Ralph N
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27118756
[No Abstract] [Full Text] [Related]
23. Why R-CHOP for first line treatment of chronic lymphocytic leukemia?
Smolej L
Int J Lab Hematol; 2007 Dec; 29(6):478-9; author reply 479. PubMed ID: 17988306
[No Abstract] [Full Text] [Related]
24. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
25. When and how to treat chronic lymphocytic leukemia.
Dighiero G; Binet JL
N Engl J Med; 2000 Dec; 343(24):1799-801. PubMed ID: 11114321
[No Abstract] [Full Text] [Related]
26. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Visentin A; Briani C; Imbergamo S; Frezzato F; Angelini A; Fedrigo M; Cacciavillani M; Altinier S; Piazza F; Semenzato G; Adami F; Trentin L
Hematol Oncol; 2018 Feb; 36(1):366-369. PubMed ID: 28971495
[TBL] [Abstract][Full Text] [Related]
27. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
Oberoi SS; Abou Jawde RM
J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
[No Abstract] [Full Text] [Related]
28. Chronic lymphocytic leukemia and Hodgkin's disease. Clinicopathologic study of three cases with good prognosis.
Serratrice De Roux C; Coso D; Bouabdallah R; Serratrice J; Disdier P; Weiller PJ
Haematologica; 2000 Aug; 85(8):878-9. PubMed ID: 10942943
[No Abstract] [Full Text] [Related]
29. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous occurrence of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.
Bueno J; Irriguible MD; Palacio C
Haematologica; 2002 Apr; 87(4):EIM11. PubMed ID: 11940498
[No Abstract] [Full Text] [Related]
31. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
[TBL] [Abstract][Full Text] [Related]
32. Promising results Halt phase III studies of idelalisib.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E9. PubMed ID: 25764575
[No Abstract] [Full Text] [Related]
33. In Remission: A Patient's Experience of Continued Care After Chronic Lymphocytic Leukemia.
Schorr A; Schorr E
Clin J Oncol Nurs; 2018 Apr; 22(2):132-133. PubMed ID: 29547611
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Keating MJ; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs CC; Freireich EJ; McCredie KB
J Clin Oncol; 1991 Jan; 9(1):44-9. PubMed ID: 1702145
[TBL] [Abstract][Full Text] [Related]
35. In vitro drug-induced cytotoxicity predicts clinical response to high-dose chlorambucil in B-cell chronic lymphocytic leukemia.
Callea V; Stelitano C; Callea I; Console G; Brugiatelli M; Morabito F
Haematologica; 1999 Sep; 84(9):863-4. PubMed ID: 10477466
[No Abstract] [Full Text] [Related]
36. Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response.
Marchand L; Paulus V; Fabien N; Pérol M; Thivolet C; Vouillarmet J; Saintigny P
J Thorac Oncol; 2017 Nov; 12(11):e182-e184. PubMed ID: 29074210
[No Abstract] [Full Text] [Related]
37. Huge kidneys in a patient with chronic lymphocytic leukaemia.
Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
[No Abstract] [Full Text] [Related]
38. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
[TBL] [Abstract][Full Text] [Related]
39. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy.
Narayan H; Bandyopadhyay D; Schmidt K; Chachlani N; Hughes M; Paneesha S; Rose P; Borg A
Clin Lab Haematol; 2005 Dec; 27(6):405-8. PubMed ID: 16307545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
